A Post Hoc Sensitivity Analysis of Survival Probabilities in a Multinational Phase III Trial of Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Decitabine should be considered as a treatment option for older patients with AML and poor prognostic risk factors.